Ocular Therapeutix Inc (OCUL)
10.27
-0.12
(-1.16%)
USD |
NASDAQ |
Nov 04, 16:00
10.24
-0.04
(-0.34%)
After-Hours: 20:00
Ocular Therapeutix Enterprise Value: 1.209B for Nov. 4, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 04, 2024 | 1.209B |
| November 01, 2024 | 1.227B |
| October 31, 2024 | 1.249B |
| October 30, 2024 | 1.335B |
| October 29, 2024 | 1.369B |
| October 28, 2024 | 1.380B |
| October 25, 2024 | 1.344B |
| October 24, 2024 | 1.305B |
| October 23, 2024 | 1.301B |
| October 22, 2024 | 1.369B |
| October 21, 2024 | 1.380B |
| October 18, 2024 | 1.374B |
| October 17, 2024 | 1.337B |
| October 16, 2024 | 1.396B |
| October 15, 2024 | 1.203B |
| October 14, 2024 | 1.238B |
| October 11, 2024 | 1.132B |
| October 10, 2024 | 1.045B |
| October 09, 2024 | 1.058B |
| October 08, 2024 | 1.061B |
| October 07, 2024 | 1.086B |
| October 04, 2024 | 1.142B |
| October 03, 2024 | 1.047B |
| October 02, 2024 | 1.059B |
| October 01, 2024 | 1.020B |
| Date | Value |
|---|---|
| September 30, 2024 | 963.96M |
| September 27, 2024 | 960.84M |
| September 26, 2024 | 976.43M |
| September 25, 2024 | 985.79M |
| September 24, 2024 | 946.81M |
| September 23, 2024 | 926.54M |
| September 20, 2024 | 1.008B |
| September 19, 2024 | 1.017B |
| September 18, 2024 | 1.019B |
| September 17, 2024 | 973.32M |
| September 16, 2024 | 999.82M |
| September 13, 2024 | 1.011B |
| September 12, 2024 | 965.52M |
| September 11, 2024 | 923.42M |
| September 10, 2024 | 910.95M |
| September 09, 2024 | 910.95M |
| September 06, 2024 | 915.63M |
| September 05, 2024 | 923.42M |
| September 04, 2024 | 921.86M |
| September 03, 2024 | 909.39M |
| August 30, 2024 | 982.67M |
| August 29, 2024 | 942.13M |
| August 28, 2024 | 1.009B |
| August 27, 2024 | 1.017B |
| August 26, 2024 | 1.012B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
106.25M
Minimum
Nov 12 2019
1.663B
Maximum
Dec 22 2020
535.36M
Average
400.90M
Median
Oct 22 2021
Enterprise Value Benchmarks
| Marinus Pharmaceuticals Inc | 10.41M |
| 4D Molecular Therapeutics Inc | -117.09M |
| Lyell Immunopharma Inc | -163.44M |
| NovaBay Pharmaceuticals Inc | 3.645M |
| Palatin Technologies Inc | 13.74M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -43.78M |
| Revenue (Quarterly) | 16.44M |
| Total Expenses (Quarterly) | 60.03M |
| EPS Diluted (Quarterly) | -0.26 |
| Gross Profit Margin (Quarterly) | 90.82% |
| Profit Margin (Quarterly) | -266.3% |
| Earnings Yield | -13.15% |
| Normalized Earnings Yield | -12.22 |